TheWell Bioscience Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Series B
- (In Progress)
- Investors
-
2
TheWell Bioscience General Information
Description
Operator of an animal-origin-free three-dimensional cell culture platform intended to accelerate drug discovery, regenerative medicine, and the development of alternative methods for biological research. The company offers synthetic hydrogels, cell culture media, growth factors, specialized cultureware, and optimized workflows, enabling pharmaceutical companies, biotechnology firms, and research institutions to develop reproducible, scalable models for organoid research, cancer studies, stem cell research, cell therapy, and tissue engineering.
Contact Information
Website
www.thewellbio.comCorporate Office
- 1 Deerpark Drive
- Suite C
- Monmouth Junction, NJ 08852
- United States
Corporate Office
- 1 Deerpark Drive
- Suite C
- Monmouth Junction, NJ 08852
- United States
TheWell Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 15-Oct-2026 | In Progress | Generating Revenue | |||
| 2. Corporate | 19-Apr-2024 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 01-Nov-2020 | Completed | Generating Revenue |
TheWell Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TheWell Bioscience Patents
TheWell Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026227059-A1 | A novel 3d cell model involving epithelial-to-mesenchymal transition for biomedical application | Pending | 26-Apr-2025 | ||
| AU-2024353260-A1 | 3d hydrogel system for cell scale-up and bioproduction | Pending | 25-Sep-2023 | ||
| EP-4784723-A1 | 3d hydrogel system for cell scale-up and bioproduction | Pending | 25-Sep-2023 | ||
| US-20250101359-A1 | 3d hydrogel system for cell scale-up and bioproduction | Pending | 25-Sep-2023 | ||
| WO-2025072243-A1 | 3d hydrogel system for cell scale-up and bioproduction | Inactive | 25-Sep-2023 | C12M25/16 |
TheWell Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TheWell Bioscience Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sartorius | Corporation | Minority | ||
| Hyper Accelerator | Accelerator/Incubator |
TheWell Bioscience FAQs
-
When was TheWell Bioscience founded?
TheWell Bioscience was founded in 2017.
-
Where is TheWell Bioscience headquartered?
TheWell Bioscience is headquartered in Monmouth Junction, NJ.
-
What is the size of TheWell Bioscience?
TheWell Bioscience has 19 total employees.
-
What industry is TheWell Bioscience in?
TheWell Bioscience’s primary industry is Biotechnology.
-
Is TheWell Bioscience a private or public company?
TheWell Bioscience is a Private company.
-
What is TheWell Bioscience’s current revenue?
The current revenue for TheWell Bioscience is .
-
Who are TheWell Bioscience’s investors?
Sartorius and Hyper Accelerator have invested in TheWell Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
